About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Publications
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
OncoFAP Radio Conjugates (Imaging)
OncoFAP Radio Conjugates (Therapy)
OncoFAP-GlyPro-MMAE
OncoACP3 (Imaging)
OncoACP3 (Therapy)
OncoCAIX
Press Releases & Media
Press Releases
Events
Media Library
Philogen in the news
Work with us
Careers
Partnering
Investors
Investor Relations
Shareholding
IPO
Press Releases
Financial Statements
Financial Calendar
Internal Dealing
Buyback
Analyst Coverage
Webinars
IR Contacts
Governance
Board of Directors
Board of Statutory Auditors
Documents & Procedures
Shareholders’ Meetings
Codice etico e Modello 231
Sustainability (ESG)
Governance
Investors
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Publications
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
OncoFAP Radio Conjugates (Imaging)
OncoFAP Radio Conjugates (Therapy)
OncoFAP-GlyPro-MMAE
OncoACP3 (Imaging)
OncoACP3 (Therapy)
OncoCAIX
Press Releases & Media
Press Releases
Events
Philogen in the news
Media Library
Work with us
Careers
Partnering
Home
$
Governance
$
By-laws
By-laws
Board of Directors
Board of Statutory Auditors
Documents & Procedures
By-laws
Shareholders’ Meetings
Incentive Plans
Codice etico e Modello 231
Whistleblowing
Sustainability (ESG)
Statuto in vigore dal 20 maggio 2025
Statuto in vigore dal 20 maggio 2025 - mark up
Statuto in vigore dal 27 maggio 2024
Statuto in vigore dal 27 maggio 2024 – mark up
Statuto in vigore dal 18 maggio 2023
Statuto in vigore dal 18 maggio 2023 – mark up
Statuto dal 21 giugno 2021
Statuto dal 3 marzo 2021
